Accelerate Diagnostics, Inc.

AXDXNASDAQHealthcare

$0.03

+$0.00(+0.00%)

Market Cap$859918

P/E Ratio—

52W High$2.09

52W Low$0.01

Avg Volume1.9M

Open$0.08

Beta0.22

Cash on Hand Financials Revenue

Accelerate Diagnostics, Inc. (AXDX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

AXDX · cash on hand · updated Dec 31, 2024

Core cash position

as of Dec 31, 2024

Cash & Short-Term Investments (CCE + ST Investments)

$16.3M▲ +23.3% vs prior year

FY · as of Dec 31, 2024 · Reported in USD

Cash & Cash Equiv. (CCE)

$15.1M

cashAndCashEquivalents

Short-Term Investments

$1.2M

shortTermInvestments

YoY Change vs Prior Year

+23.3%

vs prior fiscal year

Latest Quarter

$16.3M

Q4 2024

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2024

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$16.3MCash on Hand

Total Debt$66.6MTotal Debt

Net Cash / Net Debt−$50.3MNet Debt Position

Cash vs Debt Ratio

Cash 20%Accelerate Diagnostics, Inc. cash as % of market cap: 1895.18%% · MCap $0BDebt 80%

Accelerate Diagnostics, Inc. carries a net debt position of $50.3M. Total debt ($66.6M) exceeds cash on hand ($16.3M). Accelerate Diagnostics, Inc. cash vs debt ratio: 20% cash / 80% debt.

Net Cash = Cash & ST Investments − Total Debt$16.3M − $66.6M = −$50.3M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

AXDX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

AXDX cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2024LatestFY$16.3M+23.3%

Dec 31, 2023FY$13.2M-71.0%

Dec 31, 2022FY$45.6M-28.4%

Dec 31, 2021FY$63.6M-6.8%

Dec 31, 2020FY$68.3M-37.1%

AXDX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

AXDX vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Accelerate Diagnostics, Inc.YOU

AXDX

$16.3M$1M1895.2%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Accelerate Diagnostics, Inc. (AXDX) cash on hand as of December 31, 2024 is $16.3M, comprising $15.1M in cash and cash equivalents (CCE) plus $1.2M in short-term investments — reported as Accelerate Diagnostics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Accelerate Diagnostics, Inc. cash reserves or cash position.

Accelerate Diagnostics, Inc. annual cash on hand history shows increased +23.3% in 2024: increased +23.3% in 2024. Accelerate Diagnostics, Inc. cash reserves in 2024 reflect the company's capital allocation strategy.

Accelerate Diagnostics, Inc. carries total debt of $66.6M against cash of $16.3M, resulting in a net debt position of -$50.3M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

AXDX cash on hand · 5 questions

As of December 31, 2024, Accelerate Diagnostics, Inc. (AXDX) has $16,297,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $15,098,000 in cash and cash equivalents (CCE) plus $1,199,000 in short-term investments. Latest quarter (December 31, 2024): $16,297,000. Data sourced from the annual 10-K filing via FMP.

AXDX cash on handAXDX cash reservesAXDX cash 2024how much cash does AXDX have

▸ Source: FMP /balance-sheet-statement · US GAAP · Accelerate Diagnostics, Inc. · Accelerate Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2024